Vasopressors and Inotropes as Predictors of Mortality in Acute Severe Cardiogenic Shock Treated With the Impella Device

被引:10
|
作者
Rohm, Charlene L. [1 ]
Gadidov, Bogdan [2 ]
Ray, Herman E. [2 ,3 ]
Mannino, Salvatore F. [4 ]
Prasad, Rajnish [4 ]
机构
[1] Wellstar Kennestone Reg Med Ctr, Dept Internal Med, Marietta, GA USA
[2] Kennesaw State Univ, Analyt & Data Sci Inst, Kennesaw, GA 30144 USA
[3] Kennesaw State Univ, Dept Stat & Analyt Sci, Kennesaw, GA 30144 USA
[4] Wellstar Kennestone Reg Med Ctr, Wellstar Cardiovasc Med, Marietta, GA USA
关键词
Vasopressors; Inotropes; Cardiogenic shock; Impella; HEART-FAILURE; DOBUTAMINE; MILRINONE; DOPAMINE; NOREPINEPHRINE; EFFICACY;
D O I
10.1016/j.carrev.2020.12.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Vasopressors and inotropes are the primary pharmacologic agents in the management of cardiogenic shock. Increased use of these agents in the setting of cardiogenic shock treated with the Impella is associated with increased mortality. This study evaluates the use of vasopressors and inotropes as predictors of mortality in patients treated with the Impella for acute cardiogenic shock. Methods: This retrospective study included 276 patients treated with the Impella 2.5, Impella CP, or Impella 5.0 from March 2011 to January 2020 at a single, tertiary referral center for acute cardiogenic shock. Results: All-cause in-hospital mortality was 44.6%. Mortality significantly increased with escalating use of vasopressors and inotropes, with the most significant increase in mortality fromuse of 2 agents to the use of 3 agents (8.1% vs 39.7%, p < 0.001). There was no difference in mortality whether dobutamine or milrinone was used (44.4% vs 35.7%, p = 0.41); there was increased mortality with use of multiple inotropes. Patients treated with only vasopressors had increasedmortality compared to those treatedwith a combination of agents that included 1 inotrope. Conclusions: The escalating need for vasopressors and inotropes and particular combinations of these agents are significant predictors of mortality that may help determine whether the Impella or higher level of support is more appropriate to treat acute cardiogenic shock. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 50 条
  • [31] Incidence of Hemolysis in Patients with Cardiogenic Shock Treated with Impella Percutaneous Left Ventricular Assist Device
    Badiye, Amit P.
    Hernandez, Gabriel A.
    Novoa, Italo
    Chaparro, Sandra V.
    ASAIO JOURNAL, 2016, 62 (01) : 11 - 14
  • [32] mortality in patients with cardiogenic shock treated with the impella cp microaxial pump for left ventricular failure
    Sieweke, J. T. Jan-Thorben
    Berliner, D.
    Tongers, J.
    Napp, L. C.
    Flierl, U.
    Zauner, F.
    Bauersachs, J.
    Schaefer, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 281 - 282
  • [33] Cardiogenic shock secondary to severe acute ischemic mitral regurgitation managed with an impella 2.5 percutaneous left ventricular assist device
    Harmon, Laura
    Boccalandro, Fernando
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2012, 79 (07) : 1129 - 1134
  • [34] Real-life use of vasopressors and inotropes in cardiogenic shock—observation is necessarily ‘theory-laden’
    Samiran Ray
    Mirjana Cvetkovic
    Daniel H. Lutman
    Nazima Pathan
    Padmanabhan Ramnarayan
    David P. Inwald
    Mark J. Peters
    Critical Care, 20
  • [35] Inotropes and mortality in patients with cardiogenic shock: more questions than answers
    Lother, Achim
    Staudacher, Dawid L.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2025,
  • [36] The Therapeutic Use of Impella Device in Cardiogenic Shock: A Systematic Review
    Tello, Carlos Munoz
    Jamil, Dawood
    Tran, Hadrian Hoang-Vu
    Mansoor, Mafaz
    Butt, Samia Rauf
    Satnarine, Travis
    Ratna, Pranuthi
    Sarker, Aditi
    Ramesh, Adarsh Srinivas
    Mohammed, Lubna
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)
  • [37] An Assessment of Patient Selection for Impella Device Implantation in Cardiogenic Shock
    Amancherla, Kaushik
    Lazzara, Gina
    Schlendorf, Kelly
    O'Leary, Jared
    Zalawadiya, Sandip
    Lindenfeld, JoAnn
    Menachem, Jonathan N.
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S156 - S156
  • [38] IMPELLA SUPPORT FOR CARDIOGENIC SHOCK SECONDARY TO ACUTE MYOCARDITIS
    Charalambous, Marinos
    Meraj, Perwaiz
    Jauhar, Rajiv
    Donnelly, Joseph
    Mignatti, Andrea
    Singh, Avneet
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 815 - 815
  • [39] PREDICTORS OF IN-PATIENT MORTALITY IN PATIENTS ON SHORT-TERM LOW-DOSE INOTROPES FOR CARDIOGENIC SHOCK
    Nandkeolyar, Shuktika
    Doctorian, Tanya
    Fraser, Gary
    Ryu, Rachel
    Kagabo, Whitney
    Fearon, Colleen
    Tryon, David
    Hauschild, Chris
    Stoletniy, Liset
    Abramov, Dmitry
    Hilliard, Anthony A.
    Sakr, Antoine
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 769 - 769
  • [40] REFRACTORY PERIPARTUM CARDIOGENIC SHOCK SUCCESSFULLY TREATED WITH ECMO AND IMPELLA
    Xi, Qianlan
    Pyi Phyo Aung
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 3611 - 3611